Evidence map›Paper›PMID 36012711›Full record

ArticleInternational journal of molecular sciences2022

An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer's Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model.

Keren Nitzan, Leah Ellenbogen, Ziv Bentulila, Dekel David, Motty Franko, Emanuela P Break, Michal Zoharetz, Alon Shamir, Yosef Sarne, Ravid Doron

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. ΔInternational journal of molecular sciences · 2023
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Keren NitzanDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.ORCID 0000-0001-6193-9431
Leah EllenbogenDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.
Ziv BentulilaDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.ORCID 0000-0001-6751-6800
Dekel DavidDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.
Motty FrankoDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.
Emanuela P BreakDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.
Michal ZoharetzDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.
Alon ShamirFaculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Yosef SarneDepartment of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Ravid DoronDepartment of Education and Psychology, The Open University, Ra'anana 4353701, Israel.ORCID 0000-0002-6523-9886
Open University of Israel · ILTechnion – Israel Institute of Technology · ILTel Aviv University · IL

Funding

National Institute for PsychobiologyThe Open University of Israel research fund
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common form of dementia, but there is still no available treatment. Δ9-tetrahydrocannabinol (THC) is emerging as a promising therapeutic agent. Using THC in conventional high doses may have deleterious effects. Therefore, we propose to use an ultra-low dose of THC (ULD-THC). We previously published that a single injection of ULD-THC ameliorated cognitive functioning in several models of brain injuries as well as in naturally aging mice. Here, 5xFAD AD model mice received a single treatment of ULD-THC (0.002 mg/kg) after disease onset and were examined in two separate experiments for cognitive functions, neurotropic, and inflammatory factors in the hippocampus. We show that a single injection of ULD-THC alleviated cognitive impairments in 6- and 12-month-old 5xFAD mice. On the biochemical level, our results indicate an imbalance between the truncated TrkB receptor isoform and the full receptor, with AD mice showing a greater tendency to express the truncated receptor, and ULD-THC improved this imbalance. We also investigated the expression of three AD-related inflammatory markers and found an ameliorating effect of ULD-THC. The current research demonstrates for the first time the beneficial effects of a single ultra-low dose of THC in a mouse model of AD after disease onset.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAnimalsDisease Models, AnimalDronabinolMiceMice, TransgenicReceptor, trkBDronabinolReceptor, trkB5xFAD mice modelAlzheimer’s diseasecognitionfull TrkB receptortruncated TrkB receptorultra-low dose of THC

Identifiers

PMID36012711
PMCPMC9408848
OpenAlexW4293779489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.